TEVIMBRA is a unique PD-1 inhibitor, optimally designed for potent PD-1 binding and more robust T-cell activation1-3
See what makes TEVIMBRA different in this short video:
Clinical significance of preclinical data has not been established. No head-to-head clinical trials between products have been performed.
In preclinical models, TEVIMBRA demonstrated potent PD-1 binding for a near total blockade of PD-L11
TEVIMBRA inhibited PD-1/PD-L1 interaction with high binding affinity.
In preclinical models, TEVIMBRA demonstrated robust T-cell activation2-3
TEVIMBRA was specifically engineered to increase the number of activated T cells by preventing its binding to FcγR on macrophages, thereby preventing T-cell clearance. Other PD-1 inhibitors, such as nivolumab and pembrolizumab, can easily bind to the FcγR.
T-cell depletion may be especially relevant in the macrophage-rich environment of the peritoneum.
Clinical significance of preclinical data has not been established. No head-to-head clinical trials between products have been performed.
.
TEVIMBRA Mechanism of Action
Dr. Ronan J. Kelly, MD, MBA, discusses how TEVIMBRA is optimally designed.